# BMG Incorporated

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bmg

- Industry: Materials
- Headquarters: Kyoto-shi, Japan
- Website: www.bmg-inc.com/
- Total disclosed funding: $10M
- Latest round: Series B (Dec 17, 2021)
- Investors on record: 5

## About

Based in Japan, BMG Incorporated develops and manufactures innovative biomedical products, focusing on biodegradable materials for medical applications, enhancing surgical outcomes and patient health.BMG Incorporated, founded in 1983 in Kyoto-shi, Japan, specializes in biomedical product development and manufacturing. The company has completed a total of 2 deals, with its most recent funding round being a Series B in December 2021, raising JPY 630 million from investors including Kyoto Capital Partners and Ono Pharmaceutical.BMG Incorporated specializes in the development and manufacture of innovative biomedical products, primarily concentrating on biodegradable materials for medical applications. Key offerings include bioabsorbable polymers branded as "BioDegmer," produced in ISO13485 compliant facilities and used in medical applications such as sutures and tissue reinforcement materials. The medical adhesive "LYDEX" is another significant product, recognized for its high safety and advanced functionality, aiming to enhance surgical outcomes while minimizing the need for secondary surgeries associated with traditional materials. BMG's products are supplied globally, with a focus on North America, Europe, and parts of Asia, catering to healthcare providers, hospitals, and research institutions.BMG Incorporated operates on a B2B transaction model, generating revenue primarily through direct sales of its medical products and collaborations in research and development with other biotech entities. The company partners with healthcare providers and distributors to effectively reach end-users, focusing on delivering tailored solutions that meet specific clinical needs. Revenue is generated from flagship products like BioDegmer polymers and LYDEX adhesives, sold through regulated procurement processes in the healthcare sector to ensure compliance with industry standards. The revenue model may also include subscription or contract-based agreements for ongoing supply to hospitals and medical facilities.BMG Incorporated plans to utilize the JPY 630 million raised in Series D funding in December 2021 for global expansion. The company is focused on launching new products and entering new markets, although specific launch dates and targeted regions are not detailed. The funding will support the company's strategy for global growth, allowing for an increase in its market presence.

## Funding rounds

- Series B, Dec 17, 2021, $5.5M — Universal Materials Incubator, Kyoto Capital Partners, Ono Pharmaceutical, TOAGOSEI
- Series A, Nov 30, 2016, $4.4M — MedVenture Partners

## Investors

- MedVenture Partners (https://capitalatlas.ai/funds/medventure-partners) — Series A
- Universal Materials Incubator (https://capitalatlas.ai/funds/universal-materials-incubator) — Series B
- Kyoto Capital Partners (https://capitalatlas.ai/funds/kyoto-capital-partners) — Series B
- Ono Pharmaceutical — Series B
- TOAGOSEI — Series B